ONC201 and Paclitaxel in Treating Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Case Medical Research ◽

10.31525/ct1-nct04055649 ◽

2019 ◽

Author(s):

Keyword(s):

Fallopian Tube ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Resistant Refractory ◽

Platinum Resistant

Download Full-text

Anti-LeY monoclonal antibody (mAb) hu3S193 (Rebmab 100) in patients with advanced platinum resistant/refractory (PRR) ovarian cancer (OC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.5078 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 5078-5078 ◽

Author(s):

O. Smaletz ◽

M. D. P. Diz ◽

C. C. Carmo ◽

J. Sabbaga ◽

G. F. Cunha ◽

...

Keyword(s):

Ovarian Cancer ◽

Monoclonal Antibody ◽

Fallopian Tube ◽

Fallopian Tube Cancer ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Resistant Refractory ◽

Platinum Resistant

Download Full-text

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Case Medical Research ◽

10.31525/ct1-nct03907527 ◽

2019 ◽

Author(s):

Keyword(s):

T Cells ◽

Fallopian Tube ◽

Immune Cells ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Car T Cells ◽

Platinum Resistant ◽

Download Full-text

Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Yearbook of Oncology ◽

10.1016/j.yonc.2011.07.017 ◽

2011 ◽

Vol 2011 ◽

pp. 78-79

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Cancer ◽

Fallopian Tube ◽

Clinical Activity ◽

Fallopian Tube Cancer ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Platinum Resistant

Download Full-text

A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Annals of Oncology ◽

10.1093/annonc/mdx372.061 ◽

2017 ◽

Vol 28 ◽

pp. v352-v353

Author(s):

K.N. Moore ◽

K.A. Cadoo ◽

S. Chambers ◽

S. Ghamande ◽

G. Konecny ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Primary Peritoneal Cancer ◽

Multicentre Phase ◽

Peritoneal Cancer ◽

Platinum Resistant

Download Full-text

Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.5571 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5571-5571 ◽

Author(s):

Iurie Bulat ◽

Kathleen N. Moore ◽

Alexei Haceatrean ◽

John Woojune Chung ◽

Prabhu Rajagopalan ◽

...

Keyword(s):

Fallopian Tube ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Antibody Drug Conjugate ◽

Primary Peritoneal Cancer ◽

Phase Ib ◽

Peritoneal Cancer ◽

Drug Conjugate ◽

Platinum Resistant ◽

Download Full-text

Saracatinib (AZD0530) plus weekly paclitaxel in platinum resistant ovarian, fallopian tube or primary peritoneal cancer

http://isrctn.org/> ◽

10.1186/isrctn32163062 ◽

2012 ◽

Author(s):

Lee Webber

Keyword(s):

Fallopian Tube ◽

Weekly Paclitaxel ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Platinum Resistant

Download Full-text

Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Yearbook of Medicine ◽

10.1016/s0084-3873(11)00209-4 ◽

2011 ◽

Vol 2011 ◽

pp. 156-157

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Cancer ◽

Fallopian Tube ◽

Clinical Activity ◽

Fallopian Tube Cancer ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Platinum Resistant

Download Full-text

5002 ORAL Results from a Phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71174-6 ◽

2007 ◽

Vol 5 (4) ◽

pp. 311-312

Author(s):

S. Makhija ◽

D. Glenn ◽

F. Ueland ◽

D. Dizon ◽

V. Paton ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Double Blind Trial ◽

Double Blind ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Blind Trial ◽

Platinum Resistant

Download Full-text

840P Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.979 ◽

2020 ◽

Vol 31 ◽

pp. S630

Author(s):

L. Xia ◽

Q. Zhou ◽

Y. Zhang ◽

Y. Gao ◽

W. Hu ◽

...

Keyword(s):

Cervical Cancer ◽

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Cervical Cancer ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Multicenter Phase ◽

Platinum Resistant

Download Full-text

Phase II trial of weekly nab-paclitaxel with GM-CSF as an immune modulator in recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer: Clinical and immune responses.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5580 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5580-5580

Author(s):

John Ben Liao ◽

Ron E. Swensen ◽

Jessica Reichow ◽

Kelsie J Ovenell ◽

Jennifer Childs ◽

...

Keyword(s):

Immune Responses ◽

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Trial ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Immune Modulator ◽

Gm Csf ◽

Platinum Resistant

Download Full-text